Topcon (7732) Q4 2025 earnings summary

Executive summary

• FY2024 net sales were ¥216.0B, flat year-over-year, but operating income fell 21% to ¥8.8B and net income dropped 91.5% to ¥0.4B.

• Positioning Business faced demand slump and policy uncertainty, leading to lower sales and profits despite reforms.

• Eye Care Business achieved record-high sales and operating income, with strong growth outside China and a successful U.S. direct sales transition.

• Company will be delisted following a tender offer and MBO by TK Co., Ltd. (KKR-backed), with no FY2025 guidance provided.

• Comprehensive income was negative ¥437 million, reversing from ¥17,757 million in the prior year.

Financial highlights

• Consolidated net sales: ¥216.0B (YoY -0.2%), operating income: ¥8.8B (YoY -21%), net income: ¥0.4B (YoY -91.5%).

• Gross profit ratio declined to 52.7% (down 0.3pt YoY); gross profit was ¥113.9B.

• Basic earnings per share fell to ¥3.96 from ¥46.90 YoY.

• Operating profit margin decreased to 4.1% from 5.2% YoY.

• Shareholders' equity ratio declined to 41.5% from 43.8% YoY.

Outlook and guidance

• No FY2025 consolidated business forecasts due to planned delisting after tender offer.

• Long-term vision unchanged; targeting ¥400B net sales by 2032, focusing on reforms, new products, and M&A.

• Accelerating investment in Eye Care and digital transformation initiatives.